和黄医药-话题@MedSci - williamhill asia

#和黄医药#

6篇内容 | 1045人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1821711, encodeId=33e01821e1119, content=2021年度中国<a href='/topic/show?id=68dd104e44bd' target=_blank style='color:#2F92EE;'>#生物医药企业创新力#</a>百强出炉，<a href='/topic/show?id=dc2552824c6' target=_blank style='color:#2F92EE;'>#恒瑞#</a>、<a href='/topic/show?id=85bf39e7247' target=_blank style='color:#2F92EE;'>#和黄医药#</a>、<a href='/topic/show?id=ac55e188816' target=_blank style='color:#2F92EE;'>#百济神州#</a>、<a href='/topic/show?id=0d36104e459d' target=_blank style='color:#2F92EE;'>#传奇生物#</a>摘下桂冠, objectTitle=2021年度中国生物医药企业创新力百强出炉，恒瑞、和黄医药、百济神州、传奇生物摘下桂冠, objectType=article, longId=739912, objectId=0b8ce39912aa, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220915/c2979ee1bc2446e6a4df27fe036e0c34.jpg, objectUrl=/article/show_article.do?id=0b8ce39912aa, replyNumber=0, likeNumber=97, createdTime=2022-09-19, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b8ce39912aa, moduleTitle=2021年度中国生物医药企业创新力百强出炉，恒瑞、和黄医药、百济神州、传奇生物摘下桂冠, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0b8ce39912aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1763794, encodeId=7c101e63794ec, content=<a href='/topic/show?id=85bf39e7247' target=_blank style='color:#2F92EE;'>#和黄医药#</a>, objectTitle=和黄医药与美国Epizyme将开展表观遗传学药物的开发与商业化, objectType=article, longId=215484, objectId=c5ca215484fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5ca215484fd, replyNumber=0, likeNumber=81, createdTime=2021-08-16, rootId=0, userName=ms9608593228839890, userId=922837567286, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5ca215484fd, moduleTitle=和黄医药与美国Epizyme将开展表观遗传学药物的开发与商业化, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c5ca215484fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1763793, encodeId=d3961e6379337, content=<a href='/topic/show?id=85bf39e7247' target=_blank style='color:#2F92EE;'>#和黄医药#</a>, objectTitle=为不凡速度点赞！和黄医药重磅肿瘤新药苏泰达®获批发货仅用半月, objectType=article, longId=205754, objectId=c928205e5414, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c928205e5414, replyNumber=0, likeNumber=65, createdTime=2021-09-12, rootId=0, userName=ms9608593228839890, userId=922837567286, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c928205e5414, moduleTitle=为不凡速度点赞！和黄医药重磅肿瘤新药苏泰达®获批发货仅用半月, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c928205e5414)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1763792, encodeId=d21e1e6379289, content=<a href='/topic/show?id=85bf39e7247' target=_blank style='color:#2F92EE;'>#和黄医药#</a>, objectTitle=礼来与和黄医药共同开发的爱优特®（呋喹替尼胶囊）纳入国家医保目录, objectType=article, longId=183821, objectId=288618382189, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=288618382189, replyNumber=0, likeNumber=65, createdTime=2020-03-25, rootId=0, userName=ms9608593228839890, userId=922837567286, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=288618382189, moduleTitle=礼来与和黄医药共同开发的爱优特®（呋喹替尼胶囊）纳入国家医保目录, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=288618382189)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1763791, encodeId=031c1e637917e, content=<a href='/topic/show?id=85bf39e7247' target=_blank style='color:#2F92EE;'>#和黄医药#</a>, objectTitle=和黄医药治疗非胰腺神经内分泌瘤新药“索凡替尼”中国上市申请获受理, objectType=article, longId=182867, objectId=daaa18286e02, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daaa18286e02, replyNumber=0, likeNumber=60, createdTime=2020-06-19, rootId=0, userName=ms9608593228839890, userId=922837567286, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daaa18286e02, moduleTitle=和黄医药治疗非胰腺神经内分泌瘤新药“索凡替尼”中国上市申请获受理, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=daaa18286e02)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1763790, encodeId=61911e63790a7, content=<a href='/topic/show?id=85bf39e7247' target=_blank style='color:#2F92EE;'>#和黄医药#</a>, objectTitle=精简管线！阿斯利康放弃与和黄医药合作开发Savolitinib肾癌3期研究, objectType=article, longId=181970, objectId=dded1819e02f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dded1819e02f, replyNumber=0, likeNumber=78, createdTime=2020-04-21, rootId=0, userName=ms9608593228839890, userId=922837567286, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dded1819e02f, moduleTitle=精简管线！阿斯利康放弃与和黄医药合作开发Savolitinib肾癌3期研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=dded1819e02f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

和黄医药

2020-05-29

小小医者 (审核中...)

前往app查看评论内容

2021年度中国#生物医药企业创新力#百强出炉，#恒瑞#、#和黄医药#、#百济神州#、#传奇生物#摘下桂冠

2021年度中国生物医药企业创新力百强出炉，恒瑞、和黄医药、百济神州、传奇生物摘下桂冠

2022-09-19

ms9608593228839890 (审核中...)

前往app查看评论内容

#和黄医药#

和黄医药与美国Epizyme将开展表观遗传学药物的开发与商业化

2021-08-16

ms9608593228839890 (审核中...)

前往app查看评论内容

#和黄医药#

为不凡速度点赞！和黄医药重磅肿瘤新药苏泰达®获批发货仅用半月

2021-09-12

ms9608593228839890 (审核中...)

前往app查看评论内容

#和黄医药#

礼来与和黄医药共同开发的爱优特®（呋喹替尼胶囊）纳入国家医保目录

2020-03-25

ms9608593228839890 (审核中...)

前往app查看评论内容

#和黄医药#

和黄医药治疗非胰腺神经内分泌瘤新药“索凡替尼”中国上市申请获受理

2020-06-19

ms9608593228839890 (审核中...)

前往app查看评论内容

#和黄医药#

精简管线！阿斯利康放弃与和黄医药合作开发Savolitinib肾癌3期研究

2020-04-21

科室
- - 订阅+
  - 更多科室
工具
服务